Rationalization of Physicochemical and Structural Requirement of Some Substituted 5-(Biphenyl-4-ylmethyl)Pyrazole as Angiotensin II Receptor Antagonist: A QSAR Approach QSAR study of 5-(Biphenyl-4-ylmethyl)Pyrazole
Iranian Journal of Pharmaceutical Sciences,
Vol. 6 No. 1 (2010),
15 January 2010
,
Page 51-58
https://doi.org/10.22037/ijps.v6.41237
Abstract
A series of angiotensin II (A II) receptor antagonist of some substituted 5-(biphenyl-4-ylmethyl) pyrazole were subjected to QSAR analysis using Hansch and Fujita-Ban model, by using combination of thermodynamic, electronic, spatial descriptor and presence or absence of substituent respectively. Several QSAR model were obtained using stepwise regression analysis. Two models from both the method were selected on the basis of the statistical value that shows good significance with AII antagonistic activity. The best QSAR models further validated by leave one out cross validation method. The studies have help to ascertain the role of different substituent in explaining the observed antagonistic activity of this analogue. From Fujita-Ban model, it is predicted that butane and propane at position 1, COOH at
position 4 are essential for activity. Group like CH2CF3 at position 1 and COOH in place of tetrazole at R3 position contribute negative to the biological activity. In Hansch model it is predicted that molar refractivity at the 1 and 3 position shows positive contribution to the biological activity. Field effect at position 4 also shows positives contribution to the biological activity. Hydrogen donar at position R3 and field effect at position 1 contributes negatively to the biological activity.
- Angiotensin II receptor antagonist
- AT1 receptor
- Fujita-Ban analysis
- Hansch analysis
- QSAR
- Renin angiotensin system
How to Cite
References
[2] Cockcroft JR, Sciberras DG, Goldberg MR, Ritter MJ. Comparision of angiotensin converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm. J Cardiovasc Pharm 1993; 22: 579-84.
[3] De Gaspro M, Jhussain A, Alexander W, Cattr KJ, Chiu AT, Drew M, Good Freiend T, Harding JW, Inagani T, Timmermans PBMWM. Proposed update of angiotensin receptor nomenclature. hypertension 1995; 25: 924-39.
[4] Timmermans PBMWM, Benfield P, Chiu AT, Herblin BF, Wong PC, Smith RD. Am J Hypertension 1992; 5: 2215-355.
[5] Nahmias C, Strosberg AD. The angiotensin AT2 receptor: Searching for signal transduction pathway and physiological function. Trends Pharmacol Sci 1995; 16: 223-5.
[6] Carini DJ, Dunica JV, Aldrich PE, Chiu AT, Johnson AL, Pieerce ME, Price WA, Santella JB, Wells GJ, Wexler RR, Wong PC, Yoo S, Timmermans, PBMWM. Nonpeptide angiotensin II receptor antagonist: The discovery of series of n-(biphenylmethyl) imidazoles as potent, orally-active antihypertensives. J Med Chem 1991; 34: 2525-7.
[7] Tute M.S. History and objectives of quantitative drug design. In: Hansch C, (editor). Comprehensive medicinal chemistry. Vol 2, 4.New York: Pergamon Press, 1990. p. 579.
[8] Kubinyi H. In: Wolff ME, (editor), Berger's medicinal chemistry and drug discovery. 5th ed.Vol. 1. New York: John Wiley and Sons Inc.,1995; p. 91.
[9] Sarathy KP, Girdhar R, Yadav MR. QSAR study by Fujita- Ban model of some substituted α, β-diaryl five membered hetrocycles as Cox-1/ Cox-2 inhibitors. Indian Drugs 2003; 40: 9-18.
[10] Almansa C, Gomez LA, Cavalcanti FL, de Arriba AF, Rafanell JG, Forn J. Synthesis and structureactivitry relationship of a new series of potent AT1 selective angiotensin II receptor antagonists: 5-(Biphenyl-4-ylmethyl) pyrazoles. J Med Chem 1997; 40: 547-58.
[11] Hansch C, Leo A. Substituent constants for correlation analysis in chemistry and biology. New York: John Wiley and Sons, 1979; p. 114.
[12] Draper NR, Smith H. Applied regression analysis.New York: John Wiley and Sons, 1996; p. 193.
[13] Chakarvarti SK, Ajmani S, Chaturvedi SC.SMRAILS-Alotus 1-2-3 spreadsheet for stepwise multiple parameter regression analysis applied to QSAR analysis. Indian J Pharm Sci 1998; 60:371-4.
[14] Gupta AK, Arokia BM, Khakhedikar SG. Valstat: Valiation program for quantitative structure acyivity relationship studies. Indian J Pharm Sci 2004; 66: 396-402.
- Abstract Viewed: 290 times
- IJPS_Volume 6_Issue 1_Pages 51-58 Downloaded: 184 times